Biotech/Life Sciences

Inventing the future of human health

why

Despite numerous breakthroughs, the transformation of early-stage research into real companies has been shockingly slow. We need to incentivize more science to propel biotech into the future.

Mahway has made and continues to make money on SaaS and fintech – the boring stuff – but we believe our biggest impact will come through our biotech platform. The world doesn't necessarily need more SaaS companies; it does need a biotech revolution. With a 100-year vision and a 1000-year plan, we're here to catalyze change and redefine what's possible in biotech. Astonishing Labs is taking a radically different approach by investing at the earliest stages of innovation. Our scientists uncover fundamental truths across various biological disciplines. These discoveries have broad implications for many diseases and could benefit large patient populations.

ASTONISHING LABS

Astonishing Labs is a holding company that commercializes groundbreaking discoveries by Nobel-caliber scientists.

By partnering directly with university lab researchers on their most advanced projects, the Astonishing team is revolutionizing the traditional biotech investment model, building platform companies, and pioneering a transformative new approach to biotech investing.

ASTONISHING LABS’ PORTFOLIO

ANTHROBOTS

Anthrobots are revolutionary cellular robots made from human tracheal cells, capable of performing therapeutic tasks without genetic modification. These programmable and personalized robots seek out damaged tissue and repair it, offering unprecedented treatment modalities unlike current FDA-approved products.

CELLJA VU

Cellja Vu offers a powerful, highly translatable platform for novel drug discovery, enabling faster timelines to FDA approval and ultimately saving more patient lives.

RARE DISEASE PLATFORM

Our cellular intelligence platform accelerates drug discovery by rapidly advancing treatments to clinical trials and identifying FDA-approved compounds, thus speeding up trials and reducing the cost of IND-enabling work.

CANCER AND BIOELECTRICITY

Every cell and tissue has a measurable bioelectric signature. In tumors, we can identify unique signatures distinct from healthy tissues. These signatures can be manipulated to diagnose and treat cancer.

AGING AND LONGEVITY

Aging and related diseases are linked to changes in bioelectric signaling. These changes can be targeted by ion channel drugs to reverse key aspects of the aging process.

Core Team

Dr. Michael Levin

Lead Scientist / Co-Founder

Distinguished Professor in the Biology department of Tufts
Director of the Tufts Center for Regenerative and Developmental Biology
Co-editor in Chief of Bioelectricity, founding Associate Editor of Collective Intelligence
Harvard Business School [President’s Program]
Degrees in CS and Biology from Tufts, PhD from Harvard University

Dr. Michael Levin, a Distinguished Professor in the Biology department at Tufts, holds the Vannevar Bush endowed Chair and serves as director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. Recent honors include the Scientist of Vision award and the Distinguished Scholar Award. His group’s focus is on understanding the biophysical mechanisms that implement decision-making during complex pattern regulation, and harnessing endogenous bioelectric dynamics toward rational control of growth and form.